Study identifier:D589BR00034
ClinicalTrials.gov identifier:NCT02446041
EudraCT identifier:N/A
CTIS identifier:N/A
Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy.
Pulmonary Disease
-
No
-
All
10000
Observational
40 Years - 99 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2017 by AstraZeneca
AstraZeneca
Healthcore
The purpose of this retrospective, non-interventional sutdy is to compare the effectiveness of ICS/LABA combination therapy in the reduction of COPD exacerbations during the 12 months after initiation of therapy between COPD patients who are adherent to the index medication and those who are non-adherent.
This retrospective, observational study will assess the effectiveness of ICS/LABA combination therapies among COPD patients new to the ICS/LABA combination therapies in the US, comparing those who are adherent to the index medication and those who are non-adherent. Adherence will be measured using the proportion of days covered with the index medication. Medical and pharmacy claims data will be used as the data source.
Location
Location
Wilmington, DE, United States
Arms | Assigned Interventions |
---|---|
ICS/LABA Patients ICS/LABA Patients following standard of care | Other: Non-Interventional Study Non-Interventional Study |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.